entertainment -WSS

entertainment

author：explore 2025-09-30 18:59:53 - browse：9827

A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT — Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How to fix the rural physician shortage in the U.S.

WSS

Intarcia’s device

International team creates first chimeric human

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Obesity now affects over 1 billion people worldwide, study finds

Senate HELP committee spars over health care workforce policies

Why getting cancer drugs just got harder for rural patients

leisure time

entertainment

knowledge

Duchenne breakthrough therapy leaves behind pioneering families

Kenai launches with $82 million for Parkinson’s stem cell therapy

Apple is now the first public company to be valued at $3 trillion

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

In age of alternative facts, a scholarly course on calling out crap

Clinical trials giant ICON acquires HumanFirst

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

BioMarin wins approval for gene therapy to treat hemophilia A

Biotech companies concerned about China biosecurity crackdown

leisure time

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

In search for therapies for solid tumors, companies turn to claudin

What Congress can do to address the rural doctor shortage

Biotech lab space demand falls sharply

Medical device lobby: We're tired of waiting on Medicare coverage

Biotech stock slump in 2023: awaiting the turnaround

hotspot

hotspot

focus

hotspot